Clinical Trial Update: Nilotinib With Radiation for High Risk Chordoma [Phase 1]

View source ↗

Summary

This Phase 1 trial update reports the combination of nilotinib with radiation for high-risk chordoma. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chordoma

Drugs mentioned

• Nilotinib (nilotinib)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Chordoma | Phase 1 | Status: COMPLETED